{"organizations": [], "uuid": "4e78660716f3b638577a547ed48c7ce1de269bba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 3, "shares": 3, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2016/10/05/103995870-GettyImages-609574240.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/19746125/device/rss/rss.xml", "section_title": "Top News and Analysis (pro)", "url": "https://www.cnbc.com/2018/02/28/mylan-earnings-fall-with-epipen-sales-weak-generic-prices.html", "country": "US", "domain_rank": 767, "title": "Mylan earnings fall with EpiPen sales, weak generic prices", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "blogs", "published": "2018-03-01T00:32:00.000+02:00", "replies_count": 0, "uuid": "4e78660716f3b638577a547ed48c7ce1de269bba"}, "author": "", "url": "https://www.cnbc.com/2018/02/28/mylan-earnings-fall-with-epipen-sales-weak-generic-prices.html", "ord_in_thread": 0, "title": "Mylan earnings fall with EpiPen sales, weak generic prices", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "mylan", "sentiment": "negative"}, {"name": "mins ago reuters  mylan", "sentiment": "neutral"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Mylan said on Wednesday its fourth-quarter earnings fell due to declining revenue from its EpiPen emergency allergy injector and weak U.S. prices for generic drugs.\nThe drugmaker reported net income of $244.3 million, or 46 cents a share, in the quarter, down from $417.5 million, or 78 cents a share, last year.\nExcluding one-time items, the company said it earned $1.43 a share. Analysts on average were expecting $1.41, according to Thomson Reuters.\nRevenue in the quarter fell 1 percent to $3.24 billion, coming in below the average analyst expectation of $3.3 billion.\nMylan forecast adjusted earnings per share in the range of $5.20 to $5.60 for 2018, in line with analyst estimates.\nWATCH: Sen. Blumenthal demands Mylan pay Medicaid for alleged EpiPen rebate shortfall show chapters Sen. Blumenthal demands Mylan pay Medicaid full $1.27 billion for alleged EpiPen rebate shortfall 5:16 PM ET Thu, 1 June 2017 | 01:01", "external_links": [], "published": "2018-03-01T00:32:00.000+02:00", "crawled": "2018-03-01T00:36:46.013+02:00", "highlightTitle": ""}